Skip to main content
Premium Trial:

Request an Annual Quote

Cenix, Debiopharm Ink Biomarker ID Deal

NEW YORK (GenomeWeb News) – Cenix BioScience and Debiopharm Group today announced a research agreement to use Cenix's technology in support of Debiopharm's drug development efforts.

Cenix's expertise in combining high-throughput screening with high-content assays in cultured human cells will be applied to identify predictive biomarkers for Debiopharm's preclinical cancer candidates. Cenix has established multiparametric microscopy-based readouts using the Definiens XD image analysis platform, which will be used in human cancer cell models to identify genes and pathways that enhance or suppress a drug's therapeutic effects.

According to the partners, "the study represents another important illustration of Debiopharm's ongoing drive to integrate cutting edge technologies and powerful post-genomic strategies towards further refining its personalized medicine approach toward the development of new therapeutics."

Financial and other terms of the deal were not disclosed.

Cenix is a preclinical contract research organization with operations in Germany, Belgium, and the US and develops reagent technologies for cell-based and in vivo applications.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.